CervoMed Inc. highlighted progress for its lead candidate neflamapimod, an oral small-molecule p38α inhibitor being developed for age-related brain disorders. The company outlined plans to initiate a Phase 3 trial in dementia with Lewy bodies in the second half of 2026, and said Phase 2a enrollment is ongoing in non-fluent variant primary progressive aphasia and recovery after ischemic stroke, with data readouts expected in mid-2026 (nfvPPA) and the second half of 2026 (RAS). The presentation also summarized prior DLB study findings, including Phase 2a results showing improvements on CDR-SB and gait measures, and Phase 2b extension-phase analyses in which participants receiving a drug product batch that achieved target plasma concentrations showed improved CDR-SB and ADCS-CGIC outcomes versus an earlier batch. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief on February 18, 2026, and is solely responsible for the information contained therein.